View press release distributed by EIN Press Access:
https://www.einpresswire.com/article/831414400/biomed-industries-unveils-promising-phase-2-results-of-na-931-first-oral-quadruple-agonist-for-obesity-at-endo-2025
SAN JOSE, CA, UNITED STATES, July 17, 2025 /EINPresswire.com/ --Biomed Industries, Inc. (Biomed) today announced that its CEO Dr. Lloyd Tran presented topline results from the Phase 2 clinical trial of NA-931 , a novel oral quadruple receptor agonist for obesity, at the for ENDO 2025, July 12-15, 2025, at the Moscone Convention Center, San Francisco.
ENDO, the annual meeting of the Endocrine Society, has led advancements in hormone science and public health for more than a century. With over 7,000 global attendees, ENDO remains the premier event for endocrinology research and clinical innovation.
Landmark Findings for a Novel Oral Therapy
Dr. Tran’s presentation, titled “NA-931 , a Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight Without Muscle Loss”, highlighted the drug’s compelling clinical profile. NA-931 represents a breakthrough approach by simultaneously targeting four metabolic hormone pathways to achieve weight loss without compromising muscle mass.
In his remarks, Dr. Tran emphasized the central role endocrinologists play in managing obesity, noting that “imbalances in hormones such as insulin, GLP-1, and thyroid hormones can not only drive weight gain but are also exacerbated by obesity itself, creating a self-reinforcing cycle.” He underscored how NA-931’s mechanism may help break this cycle through comprehensive metabolic modulation.
Phase 2 Clinical Trial Results
The Phase 2 study was a 13-week, randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and efficacy of NA-931 in 125 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity.
Body Weight Reduction
• NA-931 demonstrated dose-dependent reductions in body weight, achieving up to 13.8% mean weight loss at the 150 mg daily dose.
• This represents a 12.4% greater weight loss compared to placebo.
• 72% of NA-931-treated participants achieved ≥12% weight loss, compared to only 2% in the placebo group.
Safety and Tolerability
• Treatment-emergent adverse events (TEAEs) were generally mild and transient.
• Gastrointestinal (GI) symptoms were the most commonly reported, with 83% classified as insignificant.
• Mild nausea and vomiting were reported in 7.3%, and diarrhea in 6.3% of treated subjects.
• Importantly, no muscle loss was observed.
• There were no clinically meaningful differences in GI-related adverse events between NA-931 and placebo groups.
“The Phase 2 results of NA-931 highlight its potential as a first-in-class oral quadruple receptor agonist for weight loss, with excellent safety and efficacy,” said Dr. Lloyd L. Tran, CEO of Biomed Industries. “We are excited to advance NA-931 to Phase 3 trials and provide a more comprehensive, well-tolerated treatment for obesity.”
THE URGENT NEED FOR EFFECTIVE AND SAFE OBESITY TREATMENT
Obesity remains a critical global health challenge, contributing to comorbidities such as type 2 diabetes, cardiovascular disease, liver disease, and chronic kidney disease. More than 650 million people worldwide are affected by obesity, and this figure is expected to surpass 50% of the global population by 2035. Current treatments often target limited aspects of the condition, underscoring the need for more comprehensive therapies like NA-931.
ABOUT NA-931 :
NA-931 is the first-in-class, orally active, small-molecule quadruple receptor agonist that simultaneously targets IGF-1, GLP-1, GIP, and glucagon receptors. This multi-pathway approach restores metabolic balance and induces clinically meaningful weight loss—without muscle loss or severe side effects. In Phase 1 trials, NA-931 demonstrated potential benefits for both weight reduction and glycemic control in individuals with type 2 diabetes.
Biomed recently completed a Phase 2, randomized, double-blind, placebo-controlled, 13-week study in patients with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Topline results will be announced on June 20, 2025, at ADA 2025. (ClinicalTrials.gov ID NCT06564753)
ABOUT BIOMED INDUSTRIES, INC.
Biomed Industries, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for chronic and complex diseases. The company’s investigational pipeline targets a wide range of unmet medical needs, including:
- Alzheimer’s disease
- Major depressive disorder (MDD)
- Obesity and diabetes
- Metabolic dysfunction-associated steatohepatitis (MASH)
- Stroke and alcohol use disorder
- Rare diseases, including Rett Syndrome and Fragile X
For further information, please visit Biomed Industries' official website: https://www.biomedind.com
CONTACT
Michael Willis
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Email: media@biomedind.com
https://www.biomedind.com
For more news, please visit our News page.
For further information about Biomed Industries, Inc., please contact us.